# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2020 Earnings Results

**Report date:** 2020-11-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2020

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS — Stock Up 0.28%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $8.36 | N/A | -12.18% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future projects. They emphasized their commitment to innovation despite the EPS miss.

**Key quotes:**

> Management highlighted ongoing research and development efforts.

> They expressed confidence in the long-term potential of their pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported an EPS that was lower than expected, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.28%, likely driven by positive sentiments around their ongoing research initiatives. Investors may be focusing on the company's long-term growth potential despite the short-term earnings miss.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2020_